In the Spotlight...
KRAS-G12C inhibition-induced enrichment of MHC-Ihigh immune-active tumor cells directs immune-effector TME development to augment therapeutic efficacy
Intratumoral injection of EpCAM BITE, IL-12, and GM-CSF mRNA-LNPs blocks the growth of local treated and distant untreated tumors
Dendritic cell centric nanoengineering couples antigen acquisition and STING activation for cancer immunotherapy
Breast cancer prevention by prophylactic Lalba mRNA-LNP vaccination
Previous Digests
Breaking down the mechanism of enfortumab vedotin
September 9, 2026
Enfortumab vedotin (marketed under the brand name Padcev) is an approved antibody–drug conjugate (ADC) that targets Nectin-4 on cancer cells and delivers a payload of microtubule-disrupting monomethyl auristatin E (MMAE) to tumor cells. In recent work, Olson and Liu...
Aire-ing out a tumor’s dirty laundry: manipulating tumoral AIRE to boost antitumor immunity
September 2, 2026
The autoimmune regulator (AIRE) transcription factor in medullary thymic epithelial cells (mTECs) is essential for the negative selection of autoreactive T cells in the thymus by inducing expression of peripheral tissue-specific antigens. Chen, Pulido, et al. hypothesized that AIRE...
Fun in the sun: how melanocytes avoid immune clearance, despite UV damage
August 19, 2026
Melanocytes in human skin are regularly exposed to ultraviolet radiation (UVR) from the sun, and can accumulate substantial DNA damage without being eliminated by the immune system. In recent work published in Immunity, Lo et al. investigated how these...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ute Burkhardt
Ed Fritsch
Lauren Hitchings
Gaëlle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
